Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib

@article{Neumann2005GeneEP,
  title={Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib},
  author={Frank Neumann and N Teutsch and Slawomir Kliszewski and Simone Bork and Ulrich Steidl and Benedict Brors and Nadine Schimkus and Nicole Roes and Ulrich Germing and Barbara Hildebrandt and Brigitte Royer-Pokora and Roland Eils and Norbert Gattermann and Rainer Haas and Ralf Kronenwett},
  journal={Leukemia},
  year={2005},
  volume={19},
  pages={458-460}
}
Imatinib is a potent inhibitor of the BCR-ABL tyrosine kinase. Treatment of chronic myelogenous leukemia (CML) in different stages of disease has shown its efficacy and superiority to conventional therapies. Beside inhibition of BCR-ABL, imatinib also has inhibitory effects on other tyrosine kinases such as wildtype ABL, c-KIT and platelet-derived growth factor receptors (PDGF-R) alpha and beta. ABL interacts with several proteins involved in DNA repair mechanisms such as p73, DNA-PK and RAD51… CONTINUE READING